QNCX · As filed with the SEC
Quince Therapeutics balance sheet, by quarter
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | 115,981,000 | 18,163,000 | 5,809,000 | 6,452,000 |
| Short-term investments | — | — | 11,943,000 | 19,836,000 |
| Short-term investments | 0 | 0 | — | — |
| Prepaid expenses and other current assets | 7,430,000 | 7,417,000 | 5,144,000 | 2,914,000 |
| Total current assets | 123,411,000 | 25,580,000 | 22,896,000 | 29,202,000 |
| Property and equipment, net | 506,000 | 550,000 | 595,000 | 616,000 |
| Operating lease right-of-use assets | 0 | 415,000 | 453,000 | 481,000 |
| Intangible assets | 0 | 0 | 67,819,000 | 67,726,000 |
| Other assets | 78,000 | 78,000 | 1,760,000 | 11,874,000 |
| Total assets | 123,995,000 | 26,623,000 | 93,523,000 | 109,899,000 |
| LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||
| Current liabilities: | ||||
| Accounts payable | 4,636,000 | 5,392,000 | 2,223,000 | 3,403,000 |
| Accrued expenses and other current liabilities | 3,864,000 | 3,376,000 | 10,608,000 | 5,121,000 |
| Current portion of debt | 0 | 0 | 18,026,000 | 17,520,000 |
| Short-term contingent consideration | 0 | 0 | 12,369,000 | — |
| Total current liabilities | 8,500,000 | 8,768,000 | 43,226,000 | 26,044,000 |
| Long-term debt | — | — | 0 | 0 |
| Long-term operating lease liabilities | 0 | 293,000 | 330,000 | 359,000 |
| Long-term contingent consideration | 0 | 0 | 51,961,000 | 61,213,000 |
| Deferred tax liabilities | — | — | 0 | 5,593,000 |
| Warrant liabilities | 6,292,000 | 694,000 | 32,150,000 | 14,853,000 |
| Other long-term liabilities | 716,000 | 1,196,000 | 1,570,000 | 778,000 |
| Total liabilities | 15,508,000 | 10,951,000 | 129,237,000 | 108,840,000 |
| Mezzanine equity: | ||||
| Series C Preferred Stock, $0.001 par value, 294,370 shares and no shares designated as of June 30, 2026 and December 31, 2025, respectively; 211,301.868 and no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 143,811,000 | — | — | — |
| Stockholders' equity (deficit): | ||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value, 250,000,000 shares authorized, 1,017,063 and 278,627 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 1,000 | 14,000 | 55,000 | 54,000 |
| Additional paid in capital | 460,447,000 | 435,587,000 | 418,932,000 | 415,705,000 |
| Accumulated other comprehensive income | 4,255,000 | 4,610,000 | 5,750,000 | 6,293,000 |
| Accumulated deficit | (500,027,000) | (424,539,000) | (460,451,000) | (420,993,000) |
| Total stockholders' equity (deficit) | (35,324,000) | 15,672,000 | (35,714,000) | 1,059,000 |
| Total liabilities, mezzanine equity, and stockholders' equity (deficit) | 123,995,000 | 26,623,000 | 93,523,000 | 109,899,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.